This ones a heck of a specualive investment but it seems that the institutions are willing to stomp up the cash to back it in the long term.

Heres the latest news from Killik stocbrokers on the company..........

MEDICAL MARKETING Joint Venture

We recently highlighted Medical Marketing (MMG) as worthy of attention. The company, in which I have a personal share holding, has this morning announced the formation of a joint venture, Genvax, to develop a novel DNA vaccine platform technology.

Human trials have been underway since 2001 in areas such as Lymphoma and Myeloma but the technology has broad applications in cancer, viral and bacterial infections (hence the term platform). The technology works on boosting the immune system by teaching it to identify hard to recognise cancer proteins as foreign and destroy them. Early results from the 25 patient trial in lymphoma are encouraging and evaluation of the result is expected by March 2005. Successful results should mean big pharmaceutical groups will start to take financial and commercial interests around that time.

This looks to be the first of a series of announcements due from Medical Marketing as it has a range of predominantly cancer trials moving into the clinical stage. (news flow could push the price higher)

The stock has made good progress in recent sessions up to the mid-80p level where the company is valued at just under 40 million. ENDS.

Please DYOR

cheers GF.

Anyhow?, what do you mean Mitzy these are the hottest property around.

Give it some hype mate.

cheers GF.

You are right there GF... seen the RNS...?

Yup and heres Killik Brokers backing it.....................

And heres some of that news flow from Killik Broker morning notes...................

Medical Marketing, the UK based pharmaceutical firm, announces that it has reached agreement with its joint venture partner, Kings College London, to licence a novel hepatitis therapy. The platform technology Viratis has already demonstrated that it can prevent HIV from penetrating human cells by a process of education. The news today is that they believe it works just as well in treating Hepatitis B, a market some magnitude larger. Medical Marketing will be funding the research to the tune of around 400,000 in return for which it will increase its stake in Viratis to 72%. The stock continues its rise to 90p in early trade and whilst this announcement is some way ahead of anything hitting the clinical lab, it serves to demonstrate the value in its portfolio and relationships with the Universitiesends BUY, BUY, BUY.

cheers GF.

Wow just look at it go, up 14%, NICE.

cheers Gf

Superb chart.



cheers GF.

My previous target was for 400p year end but I am erring on the side of caution as the sp has increased too fast in the last month and therefore I am reducing the target to 120p to 200p.
Longer term I see no problem with 400p to 500p.I recall IC stating that they were a possible 10 bagger at 60p;talk of 1000p and 1500p a share is fantasy.

two quid plus will do me.

cheers GF.

Some big buys coming in.

cheers Gf.

Just being cautious GF.. look at all the buys today I've never seen so much action in MMI.. almost like panic buying..

I know ,its marvelous. 2 quid plus here we come.

cheers GF.

These are the largest volumes I have ever seen traded in MMG, this is on 'reasonable' news............ brace yourselves for when big news comes, maybe the granting of a license etc.

Keep it up........ Rob

Glad I stuck with this one, a friend of mine got bored last week!!!! At least he put his money in SEO which is also flying, luckily for me I have both and thanks to gf also DGM not to mention my IDS, bloody great year so far and I expect MMG will deliver this year, any weakness at all and I'll have more, not yet though, sometimes this falls back in between news,

What fall back it goes up every day..!

Going up like the clappers again. These are a big buy.

cheers GF.

Moving higher , now up over 11%.

cheers GF.

28/01/2005 - MMI's ruthenium cancer therapy passes independently verified safety tests


Medical Marketing International Group plc (AIM:MMG), the Cambridge, UK-based pharmaceutical development company today announces that lead ruthenium compounds within its portfolio of cancer therapies show toxicity at an even safer level than tamoxifen, one of the safest cancer drugs currently available, when tested in an industry standard laboratory model.


Independent laboratory tests show ruthenium to have a low toxicity profile
Efficacy of ruthenium shown to be better than market-leading platinum drugs
Patents recently granted in biggest markets, USA and EU giving long patent protection. Other patents are pending.



MMI has already shown that the ruthenium cancer therapies within its wholly-owned subsidiary, Oncosense, appear in laboratory tests to be more powerful than the platinum-based drugs which have been some of the most successful cancer drugs for decades and which had peak sales of $5bn. Efficacy of these compounds has also been independently demonstrated in both human cancer cells and in vivo models. MMI recently announced that patents in USA and Europe, the two biggest markets have been granted, and other patents are pending.


MMI used the Dundee-based specialist, CXR Biosciences Ltd to test the most promising ruthenium compounds for potential toxicity. A summary of the CXR results is announced today.


Mark Burton, Technical Manager at MMI said: "We chose CXR because of their highly regarded expertise in screening new drugs for harmful effects. Not only did CXR deliver the results on time and on budget, they were able to show that our ruthenium cancer therapies demonstrate a low toxicity profile. These results, when added to the existing efficacy data show that ruthenium has great clinical potential."

Dr Cliff Elcombe Director at CXR and former Senior Scientist at Zeneca said: "We feel privileged to have been chosen by MMI to carry out the safety studies on what now appears to be an extremely interesting new class of cancer drugs. The safety screens that we performed indicate that this new group of cancer therapies has enormous potential."

Executive Chairman of MMI Group, David Best, commenting on these results said: "Ruthenium is only one of MMI's portfolio of excellent drug candidates, but already data show it to be potentially the most effective drug against serious cancers like lung, colon and ovarian. This new data from CXR shows ruthenium to be potentially relatively safe too. If these results are confirmed in the clinical trials, then ruthenium may improve significantly on the standard treatment for cancer patients and become a major commercial success in a cancer therapy market that was worth $42 billion in 2004 and continues to grow in double-digit figures."

Killicks are pushing this one and NLR both of which I hold...perhaps old Kav has got it right this time around since the Tech collpase of 2000..?

Buys still coming in.

cheers GF.

A few taking weekend pocket money now. Great week for this one and should move up again next week.

cheers GF.